Wockhardt secures US FDA approval for antibiotic Zaynich

Wockhardt's novel antibiotic, Zaynich (cefepime and zidebactam), has received US FDA approval for complicated urinary tract infections. This breakthrough drug targets superbugs resistant to existing treatments. Zaynich also secured marketing authorization in India for similar infections and concurrent bacteremia, offering a significant solution to the growing threat of antimicrobial resistance.